Network Bio launched with $50 million in financing and a collaboration valued at $30 million with Nvidia to develop a cell-free RNA (cfRNA) foundation model. The Palo Alto startup plans to integrate large-scale tissue, blood, molecular, and longitudinal clinical outcome datasets from academic medical centers including Mass General Brigham, the University of Pennsylvania, and the University of Colorado Anschutz. The partnership ties Network Bio’s model-building to Nvidia software (Parabricks) and BioNeMo Recipes tooling, with the model trained using Nexus, a self-supervised transformer over cfRNA expression profiles. The planned population-scale cfRNA foundation model would serve as a basis for supervised oncology and non-oncology indication models. The launch underscores how compute infrastructure and biomedical data partnerships are increasingly becoming prerequisites for building foundation-model assets in drug discovery and biomarker work, not standalone research projects.